BAYER AG

Illumina's TruSight Oncology Comprehensive test, approved by the FDA, profiles 517 genes to match cancer patients with targeted therapies or clinical trials, aiding in personalized treatment.

EMA approves Bayer's OcuClick pre-filled syringe for Eylea 8 mg, facilitating accurate administration in wet AMD and DME treatments, with Germany as an early launch market.

Prostate Cancer Treatment Market growth driven by rising incidence, awareness, and advances in technologies like immunotherapy and targeted biologics. Market expected to grow at 5.00% CAGR from 2024 to 2031, supported by healthcare infrastructure investments and personalized medicine.

The WHO's mpox declaration led to significant stock market increases for pharmaceutical, medical tech, and biopharmaceutical companies, while airline stocks declined, reflecting investor concerns about mpox's global spread.

The oral thin films market is projected to reach $7.65 billion by 2028 with a CAGR of 13.6%, driven by specialty pharmaceuticals, precision medicine, and telemedicine. Key players include ZIM Laboratories, NAL Pharma, and Cure Pharmaceutical. The market is segmented by type, disease indication, and distribution channel.

Agricultural Biotechnology Market valued at USD 51.12B in 2023, projected to reach USD 100.32B by 2031, growing at a CAGR of 9.70%. Key drivers include food security, sustainable agriculture, consumer interest in nutrition, pest control, and advancements in gene editing. Challenges involve public perception, ethical considerations, economic access, and integration with conventional techniques. Key players include Arcadia Biosciences, Thermo Fisher Scientific, Bayer AG, Biocentury Transgene Co., Ltd, Vilmorin & Cie, Eurofins Scientific, LGC Biosearch Technologies.

BlueRock Therapeutics announced FDA clearance of its IND application for OpCT-001, an iPSC-derived cell therapy for primary photoreceptor diseases. OpCT-001 aims to restore vision by replacing degenerated retinal cells and is the first of its kind to be clinically evaluated. A Phase 1/2a study is underway to assess safety and efficacy.

Bayer presents OASIS 3 study results on elinzanetant's efficacy and safety for menopause-related VMS at TMS annual meeting. Elinzanetant, a dual NK-1 and 3 receptor antagonist, shows potential as a non-hormonal treatment. Bayer has submitted a New Drug Application to the FDA and plans to seek marketing authorizations globally.

Pharmaceutical industry faces significant challenges with over 14,000 layoffs in 2024 due to deteriorating financial performance, rising costs, and regulatory pressures. Companies like Pfizer and Takeda are cutting costs and closing R&D facilities, prioritizing short-term financial health over long-term innovation. The U.S. Inflation Reduction Act is expected to further strain the industry by reducing revenue streams starting in 2026, adding to the impact of inflation, supply chain disruptions, and patent expirations. These financial pressures force companies to streamline operations and reduce expenditures, potentially leading to slower innovation and reduced capacity to bring new therapies to market.

Finerenone reduced heart failure events and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to a Brigham and Women's Hospital-led trial. Hyperkalemia rates were higher in the finerenone group. Results published in the New England Journal of Medicine.